Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025

The primary progressive multiple sclerosis (PPMS) treatment market size is expected to see rapid growth in the next few years. It will grow to $1.92 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. This anticipated growth will be driven by the rising number of clinical trials exploring novel PPMS therapies, progress in diagnostic methods, a growing preference for precision and targeted medicine, improvements in healthcare infrastructure, and stronger collaboration and partnerships between pharmaceutical firms. Key trends expected during the forecast period include innovation in disease-modifying therapies aimed at halting PPMS progression, the application of biomarker studies for personalized treatment, enhanced imaging technologies such as MRI, advancements in neuroprotection and remyelination drug development, and breakthroughs in genetic and molecular patient profiling for more accurate treatment planning.

The growing demand for effective treatments is expected to propel the growth of the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that reduce symptoms, improve patient outcomes, or cure a disease or condition. This demand is primarily driven by the rising prevalence of chronic and complex health conditions, which require long-term management and advanced therapeutic interventions to improve patient outcomes and quality of life. These treatments help slow the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby improving long-term quality of life, reducing disability accumulation, and enhancing patients’ ability to manage daily activities with greater independence and stability. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, an increase of 10% compared to 2022, representing the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments drives the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on developing innovative formulations such as monoclonal antibody drugs to enhance the treatment of multiple sclerosis. A monoclonal antibody drug helps in multiple sclerosis by targeting specific immune cells or proteins that cause inflammation and damage to the nervous system, reducing disease activity and slowing the progression of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, to treat multiple sclerosis (MS) in India. Ocrevus is notable for being the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug works by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response seen in MS. It is administered as a twice-yearly intravenous infusion for only two hours, offering patients a more convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on providing access to medicines, partnered with Mapi Pharma Ltd. to advance the development and commercialization of GA Depot 40 mg for multiple sclerosis treatment. Through this partnership, Viatris supports the regulatory and commercial pathway for GA Depot, a long-acting injectable therapy to improve treatment adherence and address unmet medical needs in managing multiple sclerosis. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot technologies and sustained-release formulations for central nervous system disorders, including multiple sclerosis.

Major players in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary progressive multiple sclerosis (PPMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Primary progressive multiple sclerosis (PPMS) treatment encompasses medical and therapeutic strategies designed to manage and slow the progression of PPMS - a form of multiple sclerosis marked by a continuous decline in neurological function from the onset, without distinct relapses or remissions. These interventions aim to reduce disease activity, ease symptoms, preserve mobility, and enhance patients’ quality of life.

The primary drug categories utilized in the management of primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and various other drug types. Monoclonal antibodies (mAbs) are synthetically engineered proteins that specifically bind to antigens on affected cells, serving diagnostic or therapeutic functions. These medications are delivered through different routes such as oral, intravenous, and others, and are made available via hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

The primary progressive multiple sclerosis (PPMS) treatment market size has grown rapidly in recent years. It will grow from $1.02 billion in 2024 to $1.16 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. Growth during the historic period was supported by the increasing incidence of PPMS among older adults, enhanced awareness and knowledge of the condition among patients and medical professionals, higher R&D investments targeting PPMS therapies, greater use of disease-modifying treatments, and amplified governmental support and funding for emerging treatment options.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.